Tofacitinib (CP-690550) Citrate

Catalog No.S5001 Synonyms: Tasocitinib Citrate,CP-690550

For research use only.

Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.

Tofacitinib (CP-690550) Citrate Chemical Structure

CAS No. 540737-29-9

Selleck's Tofacitinib (CP-690550) Citrate has been cited by 177 publications

Purity & Quality Control

Choose Selective JAK Inhibitors

Other JAK Products

Biological Activity

Description Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.
Targets
JAK3 [1]
(Cell-free assay)
JAK2 [4]
(Cell-free assay)
1 nM 20 nM
In vitro

Tofacitinib citrate inhibits IL-2-mediated human T cell blast proliferation and IL-15-induced CD69 expression with IC50 of 11 nM and 48 nM, respectively. Tofacitinib citrate prevents mixed lymphocyte reaction with IC50 of 87 nM. Tofacitinib citrate treatment of murine factor-dependent cell Patersen–erythropoietin receptor (FDCP-EpoR) cells harboring human wild-type or V617F JAK2 leads to prevention of cell proliferation with IC50 of 2.1 µM and 0.25 µM, respectively. Tofacitinib citrate inhibits interleukin-6-induced phosphorylation of STAT1 and STAT3 with IC50 of 23 nM and 77 nM, respectively. Moreover, Tofacitinib citrate generates a significant pro-apoptotic effect on murine FDCP-EpoR cells carrying JAK2VV617F, whereas a lesser effect is observed for cells carrying wild-type JAK2. This activity is coupled with the inhibition of phosphorylation of the key JAK2V617F-dependent downstream signaling effectors signal transducer and activator of transcription (STAT)3, STAT5, and v-akt murine thymoma viral oncogene homolog (AKT). [2] Additionally, Tofacitinib citrate prevents IL-15-induced CD69 expression in human and cynomolgus monkey NK and CD8+ T cells in vitro. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 MXXGeY5kfGmxbjDhd5NigQ>? NIC4T|g{OCCvaX7z Mn3pTY5pcWKrdHnvckBw\iCqdX3hckBIW1RvZoXz[YQhUkGNMzDjZZRidHm2aXOg[I9u[WmwIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkmgZ4VtdHNidYPpcocheG:ueXfseZRidWmlIHHjbYQufHm{b4PpcoUh[XNic4Xid5Rz[XSnIHHmeIVzKDNyIH3pcpMh[nliRVzJV2EtKEurIE2gNE4xODB2IN88UU4> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4OES4OEc,OjN4Nki0PFQ9N2F-
Sf9 MYfGeY5kfGmxbjDhd5NigQ>? MY[5NEBucW6| NVjQNohYUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDOMZRmem2rbnHsJGdUXC22YXfn[YQhUkGNMzDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KHW|aX7nJGJqd3Srbj3MR{1GWUWGRWDFS2R[TkWZTFWgZZMhe3Wkc4TyZZRmKGGodHXyJFkxKG2rboOgZpkhXFJvRmLFWEBie3OjeTygTWM2OCB;IECuNFAxPiEQvF2u M3PtcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
Sf9 M{\ZOWZ2dmO2aX;uJIF{e2G7 NV3QWoRzOzBibXnudy=> M3zmSGlvcGmkaYTpc44hd2ZiaIXtZY4hT1OWLX\1d4VlKEqDS{GgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy|IIXzbY5oKHCxbInncJV1[W2rYzDhZ4llNXS7cn;zbY5mKGG|IIP1ZpN1emG2ZTDh[pRmeiB|MDDtbY5{KGK7IFXMTXNCNCCNaTC9JFAvODByNzFOwG0v M1vQcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|Nk[4OFg1Lz5{M{[2PFQ5PDxxYU6=
Sf9 M3LvdGZ2dmO2aX;uJIF{e2G7 MUCzNEBucW6| M3zwfmlvcGmkaYTpc44hd2ZiaIXtZY4hT1OWLX\1d4VlKEqDS{KgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy|IIXzbY5oKHCxbInncJV1[W2rYzDhZ4llNXS7cn;zbY5mKGG|IIP1ZpN1emG2ZTDh[pRmeiB|MDDtbY5{KGK7IFXMTXNCNCCNaTC9JFAvODByNzFOwG0v MkPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0PFQoRjJ|Nk[4OFg1RC:jPh?=
Sf9 MVrGeY5kfGmxbjDhd5NigQ>? NEf4cIpKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFfTWE11[WepZXSgTmgyKGSxbXHpckApPzh3IITvNVEzPSlib3[gTmFMOyCneIDy[ZN{\WRiaX6gbY5{\WO2IGPmPUBk\WyuczDifUBGVEmVQTygTWM2OCB;IECuNFAyKM7:TT6= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
Sf9 M3j6RmZ2dmO2aX;uJIF{e2G7 MU\Jcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiaIXtZY4hUkGNMzDjZZRidHm2aXOg[I9u[WmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[nliRVzJV2EtKEmFNUCgQUAxNjByMTFOwG0v NUDRcWxDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxNFU4OTFpPkKxNVA2PzFzPD;hQi=>
Sf9 NGH0ZnhHfW6ldHnvckBie3OjeR?= NGDSWIQ6OCCvaX7z MXXJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KE5vdHXycYlv[WxiR2PUMZRi\2enZDDKRWsyKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgeZNqdmdiQnnveIlvNUyFLVXRSWRGWEWJRGnGSXdNTSCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDUVk1HWkWWIHHzd4F6NCCLQ{WwJF0hOC5yMEOg{txONg>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB6N{e1NEc,OjJyOEe3OVA9N2F-
Sf9 Ml7mSpVv[3Srb36gZZN{[Xl? MnHoTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIHj1cYFvKEqDS{OgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGK7IFXMTXNCNCCLQ{WwJF0hOC5yMEOzJO69VS5? M4nxflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUC1O|EyLz5{MUGwOVcyOTxxYU6=
Sf9 M1vrfGZ2dmO2aX;uJIF{e2G7 MWS5NEBucW6| MkDVTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgTmFMOiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJJV{cW6pIFLpc5Rqdi2OQz3FVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDBwMEC0JO69VS5? NWj4R3BsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
SF21 MmLZSpVv[3Srb36gZZN{[Xl? MoP0NVAhdWmwcx?= M3zLOGlvcGmkaYTpc44hd2ZiSlHLNkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCVRkKxJINmdGy|IIXzbY5oKEKrb4Tpck1MSUmHVFTLSXl[XF[NRDDhd{B{fWK|dILheIUh[W6mIGuzN3Bo[W2vYW3BWHAhcW6ldXLheIVlKG[xcjCxNEBucW6|IIDybY9zKHSxIIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB|MDDtbY5{KGK7IGTvdINwfW62IHHuZYx6e2m|LDDJR|UxKD1iMD6wNFQh|ryPLh?= NHvy[209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0NVY4OCd-MkO1OFE3PzB:L3G+
insect cells MkH5SpVv[3Srb36gZZN{[Xl? M{TjfmlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDKZYsyKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMhfXOrbnegO|AhfU1iQWTQMEBKSzVyIE2gNE4xODZzIN88UU4> M3PNNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OlA2Lz5{MUG1OVYxPTxxYU6=
insect cells NHe4[5hHfW6ldHnvckBie3OjeR?= MUTJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiSnHrN{BmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIEG4JJVOKEGWUDygTWM2OCB;IECuNFA5KM7:TT6= NUHJdo5DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOVU3ODVpPkKxNVU2PjB3PD;hQi=>
T-cells MmTjSpVv[3Srb36gZZN{[Xl? NEn4bFg4OiCqcoO= MX3Jcohq[mm2aX;uJI9nKEmOMj3pcoR2[2WmIIDyc4xq\mW{YYTpc44hd2ZiaIXtZY4hXCClZXzsd{Bie3Onc4Pl[EBieyCdM1jdeIh6dWmmaX7lJIlv[2:{cH;yZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTBiPTCwMlAyOSEQvF2u M2PuPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
insect MoLoSpVv[3Srb36gZZN{[Xl? MUnJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiSnHrNkBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIEKwJJVOKEGWUDygTWM2OCB;IECuNFEzKM7:TT6= NFHnfog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVYxPSd-MkGxOVU3ODV:L3G+
MO7 M2LvbmZ2dmO2aX;uJIF{e2G7 Ml32TY5pcWKrdHnvckBw\iCMYXuzMY1m\GmjdHXkJGlNOTVvaX7keYNm\CCVdHH0OUBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gUW84KGOnbHzzJIJ6KGOnbHytZoF{\WRiYYPzZZktKEmFNUCgQUAxNjB{NDFOwG0v M1XudVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OlA2Lz5{MUG1OVYxPTxxYU6=
Ba/F3 M3rTfmZ2dmO2aX;uJIF{e2G7 MWq2NEBucW6| NX;oUJdwUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgTmFMOSCneIDy[ZN{\WRiaX6gRoEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBUXEGWNTDwbI9{eGixconsZZRqd25iYX\0[ZIhPjBibXnud{BjgSCDbIDoZXNkemWnbjDhd5NigSxiSVO1NEA:KDBwMEK2JO69VS5? MnjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
T-cells M{S1UGZ2dmO2aX;uJIF{e2G7 NF\BTIZKdmirYnn0bY9vKG:oIFrBT|MwOSCrbjDoeY1idiCWIHPlcIx{KGW6cILld5NqdmdiQ1SzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWwzNXO2aX31cIF1\WRiU2TBWFViKHCqb4PwbI9zgWyjdHnvckwhUUN3MDC9JFAvODJ6IN88UU4> NV7QcZV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDhpPkKzOVQxPjR6PD;hQi=>
PBMC M3PkXmZ2dmO2aX;uJIF{e2G7 M1TXcWlvcGmkaYTpc44hUUxvNz3pcoRkfWWmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSk2FIHPlcIx{KGK7IH\sc5ch[3m2b33leJJ6NCCLQ{WwJF0hOC5yM{mg{txONg>? MnHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7Mke0NlMoRjJ4OUK3OFI{RC:jPh?=
TF1 M3;qfGZ2dmO2aX;uJIF{e2G7 MV2yNEBucW6| NGXWWoJKdmirYnn0bY9vKG:oIFrBT|EhcW5iaIXtZY4hXEZzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUUx4LXnu[JVk\WRiU2TBWFMheGixc4Doc5J6dGG2aX;uJIlv[3WkYYTl[EBnd3JiMkCgcYlveyCob3zsc5dm\CCkeTDJUFYh[2ijbHzlcodmKG[xcjCzNEBucW6|IHnuJJBz\XOnbnPlJI9nKHeqb3zlJIJtd2:mLDDFR|UxKD1iMD6wOFMh|ryPLh?= NVXD[ZlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVkzOTRpPkKzOlU6OjF2PD;hQi=>
TF1 M17zTmZ2dmO2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGlNPi2|dHnteYxifGWmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBjgSCDbIDoZXNkemWnbjDhd5NigSxiSV7IJF0hOC5yNEWg{txONg>? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN5Mk[1N{c,OjZ|N{K2OVM9N2F-
CTLL M1zXbmZ2dmO2aX;uJIF{e2G7 MkfGTY5pcWKrdHnvckBw\iCMYXuzMY1m\GmjdHXkJGlNOi2rbnT1Z4VlKFO2YYS1JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDDWGxNKGOnbHzzJIJ6KGOnbHytZoF{\WRiYYPzZZktKEmFNUCgQUAxNjB2ODFOwG0v Ml;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNUW2NFUoRjJzMUW1OlA2RC:jPh?=
Sf9 M{TNdWZ2dmO2aX;uJIF{e2G7 M1zQe|kxKG2rboO= MVLJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KE5vdHXycYlv[WxiR2PUMZRi\2enZDDUXWszKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgeZNqdmdiQnnveIlvNUyFLVXRSWRGWEWJRGnGSXdNTSCjczDzeYJ{fHKjdHWgZYZ1\XJiOUCgcYlveyCkeTDUVk1HWkWWIHHzd4F6NCCLQ{WwJF0hOC5yNUKg{txONg>? NWrQOoRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
TF1 M{nPcWZ2dmO2aX;uJIF{e2G7 MYDJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWwzNWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:wLDDFR|UxKD1iMD6wOVMh|ryPLh?= M3\xOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUmxOFAzLz5{MkW5NVQxOjxxYU6=
TF1 M{XMWGZ2dmO2aX;uJIF{e2G7 NFPheo8zOCCvaX7z Mk\nTY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNPi2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMheHKrb4KgeI8hUUx4LXnu[JVkfGmxbjDt[YF{fXKnZDDh[pRmeiB|MDD0c{A1PSCvaX7zMEBGSzVyIE2gNE4xPTNizszNMi=> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ7OEC4OEc,OjJ4OUiwPFQ9N2F-
TF1 Mk\WSpVv[3Srb36gZZN{[Xl? MVeyNEBucW6| MXPJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWw3NWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHnuZ5Vj[XSnZDDmc5IhOjBibXnud{Bnd2yub4fl[EBjgSCLTE[gZ4hidGynbnflJIZweiB|MDDtbY5{NCCHQ{WwJF0hOC5yNUOg{txONg>? MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3OUKxOEc,OjN4NUmyNVQ9N2F-
Ba/F3 M4X6T2Z2dmO2aX;uJIF{e2G7 MkO5OlAhdWmwcx?= MWHJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCMQVuzJIV5eHKnc4Pl[EBqdiCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBi\nSncjC2NEBucW6|IHL5JGFteGijU3Py[YVvKGG|c3H5MEBKSzVyIE2gNE4xPTRizszNMi=> NHTwb4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC4O|c2OCd-MkKwPFc4PTB:L3G+
T-cells MofLSpVv[3Srb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGGubH;n[Y5q[yClZXzsd{1{fGmvdXzheIVlKHC{b3zp[oVz[XSrb36gbY4hdW:wa3X5JHQh[2WubIOgZpkhdWm6ZXSgcJlueGixY4n0[UBz\WGldHnvckBu\XSqb3SsJGlEPTBiPTCwMlA2PyEQvF2u MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
CD34+ Mon1SpVv[3Srb36gZZN{[Xl? MYHJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gR2Q{PCtiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBGWE9vbXXkbYF1\WRiY3XscEBxem:uaX\ldoF1cW:wLDDJR|UxKD1iMD6wO|Eh|ryPLh?= NELYdnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmyO|QzOyd-Mk[5Nlc1OjN:L3G+
TF1 M1rTU2Z2dmO2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKEmOND3pcoR2[2WmIIDyc4xq\mW{YYTpc44hd2ZiVF[xJINmdGy|LDDJR|UxKD1iMD6wPEDPxE1w NWLqdlhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5N|Q1PTdpPkG2PVM1PDV5PD;hQi=>
T-cells M4PhS2Z2dmO2aX;uJIF{e2G7 MUTJcohq[mm2aX;uJI9nKGGubH;n[Y5q[yClZXzsd{1{fGmvdXzheIVlKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gWEBk\WyuczDifUBucXinZDDsfY1xcG:leYTlJJJm[WO2aX;uJI1mfGixZDygTWM2OCB;IECuNFg4KM7:TT6= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
TF1 MYDGeY5kfGmxbjDhd5NigQ>? MoDNNlAhdWmwcx?= NXr2[nREUW6qaXLpeIlwdiCxZjDKRWszKGmwIHj1cYFvKFSIMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEWSTz3pcoR2[2WmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IEKwJI1qdnNicILpc5IhfG9iRWDPMYlv\HWldHnvckBu\WG|dYLl[EBi\nSncjCzNEB1dyB2NTDtbY5{NCCHQ{WwJF0hOC5yOUOg{txONg>? NY\KPYxLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2PVgxQDRpPkKyOlk5ODh2PD;hQi=>
TF1 M4XpUmZ2dmO2aX;uJIF{e2G7 NX;6U5NDOjBibXnudy=> NGDkZ2hKdmirYnn0bY9vKG:oIFrBT|IhcW5iaIXtZY4hXEZzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhTVCRLXnu[JVk\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIlv[3WkYYTl[EBnd3JiMkCgcYlveyCob3zsc5dm\CCkeTDJUFYh[2ijbHzlcodmKG[xcjCzNEBucW6|LDDFR|UxKD1iMD6wPVMh|ryPLh?= NETveHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[1PVIyPCd-MkO2OVkzOTR:L3G+
PBMC NWC1UGdJTnWwY4Tpc44h[XO|YYm= M2\6cWlvcGmkaYTpc44hd2ZiSlHLNUBqdiCqdX3hckBRSk2FIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUUxvNj3pcoR2[2WmIF3DVFEhe2WlcnX0bY9vNCCLQ{WwJF0hOC5yOUWg{txONg>? M1nlU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUK3OFI{Lz5{NkmyO|QzOzxxYU6=
TF1 NV7YU|NZTnWwY4Tpc44h[XO|YYm= MUWyJIhzew>? MV3Jcohq[mm2aX;uJI9nKEqDS{KgbY4hT02FU1[td5RqdXWuYYTl[EBpfW2jbjDUSlEh[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gV3RCXDVicHjvd5Bpd3K7bHH0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhT02FU1[gd5RqdXWuYYTpc44h\m:{IEWwJI1qdnNiYomgSmFEWyC{ZXHk[ZIh[W6jbInzbZMtKEmFNUCgQUAxNjB7NTFOwG0v MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|MEO1PUc,OjdzM{CzOVk9N2F-
TF1 MkiySpVv[3Srb36gZZN{[Xl? NV;qNWdxUW6qaXLpeIlwdiCxZjDKRWszKGmwIFXQU{1{fGmvdXzheIVlKGi3bXHuJHRHOSClZXzsd{BmgHC{ZYPzbY5oKHO2YXLsfUBqdnSnZ4LheIVlKGKndHGtcIFkfGGvYYPlJJJmeG:{dHXyJIdmdmVidX7k[ZIh[2:wdILvcEBw\iCVVFHUOUBz\XOyb37z[UBmdGWvZX70d{BqdiCrboTldoZmem:wIILl[5Vt[XSxcomg[oFkfG:{IEGg[4Vv\SCycn;tc5RmeiCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlExPyEQvF2u NFnrZnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG1OlE{Pid-MkmxOVYyOzZ:L3G+
Sf9 M{fLU2Z2dmO2aX;uJIF{e2G7 MlzPTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIHj1cYFvKEqDS{GgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGK7IFXMTXNCNCCLQ{WwJF0hOC5zMTFOwG0v M3vDclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUC1O|EyLz5{MUGwOVcyOTxxYU6=
T-cells MY\GeY5kfGmxbjDhd5NigQ>? NXvmUZdZUW6qaXLpeIlwdiCxZjDhcIxw\2WwaXOgZ4VtdHNvc4TpcZVt[XSnZDDwdo9tcW[ncnH0bY9vKGmwIH3veZNmKFRiY3XscJMh[nlibXn4[YQhdHmvcHjvZ5l1\SC{ZXHjeIlwdiCvZYToc4QtKEmFNUCgQUAxNjFzNTFOwG0v NXLMVmQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
ME180 Mn7jSpVv[3Srb36gZZN{[Xl? NIP3eoRKdmirYnn0bY9vKG:oIFrBT|EhcW5iSVy2MZN1cW23bHH0[YQhcHWvYX6gUWUyQDBiY3XscJMh\XiycnXzd4lv\yC|dHHicJkhcW62ZXfyZZRm\CCkZYThMYxi[3SjbXHz[UBz\XCxcoTldkBo\W6nIIXu[IVzKGOxboTyc4whd2Zic3nzMYlv\HWlaXLs[UBmdGWvZX70JIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMUK0JO69VS5? NIS4dG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG1OlE{Pid-MkmxOVYyOzZ:L3G+
CTLL-2 MnuwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MnrGO|IhcHK| MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFnMMVIue3SrbYXsZZRm\CCvb4Xz[UBEXEyOLUKgZ4VtdHNiZYjwdoV{e2mwZzDKRWsyN0qDS{OgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxKD1iMD6xN|Ih|ryPLh?= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd4MkKzPEc,OTl5NkKyN|g9N2F-
HT2 NWnoOI5YTnWwY4Tpc44h[XO|YYm= NUnPZ2FsUW6qaXLpeIlwdiCxZjDKRWs{KGmwIH3veZNmKEiWMjDj[YxteyCjc4Pld5Nm\CCjczDzeZBxemW|c3nvckBw\iClZXzsJIdzd3e2aDygTWM2OCB;IECuNVU3KM7:TT6= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5MUG4NEc,Ojd5N{GxPFA9N2F-
DND/L12 NHX6VmtHfW6ldHnvckBie3OjeR?= NFHRW20{OCCvaX7z M37UbWlvcGmkaYTpc44hd2ZiSlHLN{BqdiCqdX3hckBFVkRxTEGyJINmdGy|IHHmeIVzKDNyIH3pcpMh[nlibIXjbYZmemG|ZTDhd5NigSCrbjDwdoV{\W6lZTDv[kBpfW2jbjDz[ZJ2dSCjbHL1cYlvNCCLQ{mwJF0hOC5zNjFOwG0v M2jGRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
T-cells NHnj[4tHfW6ldHnvckBie3OjeR?= MmPhTY5pcWKrdHnvckBw\iCMQVuyM|EhcW5iaIXtZY4hXCClZXzsd{BmgHC{ZYPzbY5oKEOGMzDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnGUodidW2jLYP0bY12dGG2ZXSgV3RCXDFicHjvd5Bpd3K7bHH0bY9vNCCLQ{WwJF0hOC5zNzFOwG0v M4LhOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUSwOlQ5Lz5{M{W0NFY1QDxxYU6=
insect cells MmH3SpVv[3Srb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiVInrNkBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIEO1JJVOKEGWUDygTWM2OCB;IECuNVc3KM7:TT6= NIHZfWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVYxPSd-MkGxOVU3ODV:L3G+
Ba/F3 MmLqSpVv[3Srb36gZZN{[Xl? MoP6OlAhdWmwcx?= Mn3uTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiSlHLNkBmgHC{ZYPz[YQhcW5iQnGvSlMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTWGFVPSCyaH;zdIhwenmuYYTpc44h[W[2ZYKgOlAhdWmwczDifUBCdHCqYWPjdoVmdiCjc4PhfUwhUUN3MDC9JFAvOjZ3IN88UU4> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB6N{e1NEc,OjJyOEe3OVA9N2F-
TF1 MVnGeY5kfGmxbjDhd5NigQ>? MWDJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINmdGxiZ4Lve5RpNCCLQ{WwJF0hOC5{N{WxJO69VS5? NV;mNpB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|EyQDBpPkK3O|cyOThyPD;hQi=>
CD34+ MV\GeY5kfGmxbjDhd5NigQ>? Mn\hOFUhdWmwcx?= Moe1TY5pcWKrdHnvckBw\iCMQVuyJIhwdW:maX3ldkBqdiCqdX3hckBETDN2KzDj[YxteyC|cHnr[YQhcW62bzDoeY1idiC5aH;s[UBjdG:xZDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFXQU{1qdmS3Y3XkJHNVSVRvNTDwbI9{eGixconsZZRqd25icILlbY5kfWKjdHXkJIZweiB2NTDtbY5{KG[xbHzve4VlKGK7IFXQU{Bi\GSrdHnvckBu\WG|dYLl[EBi\nSncjCxOUBucW6|IHL5JGZCS1NiYX7hcJl{cXNuIFnDOVAhRSByLkOwNkDPxE1w MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{WzN{c,OjR2MUe1N|M9N2F-
A2780 Mnq0SpVv[3Srb36gZZN{[Xl? NX24WFVJUW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhVlCPIIDoc5NxcG:{eXzheIlwdiCjdDD0bJIyQTliaX6gbJVu[W5iQUK3PFAh[2WubIO= M{PXe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
A2780 MonLSpVv[3Srb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGOmaz3t[YRq[XSnZDDOVG0heGixc4Doc5J6dGG2aX;uJIF1KHSqckG5PUBqdiCqdX3hckBCOjd6MDDj[Yxtew>? M4LmS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUC1O|EyLz5{MUGwOVcyOTxxYU6=
A2780 NGjm[JhHfW6ldHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGOmaz3t[YRq[XSnZDDOVG0heGixc4Doc5J6dGG2aX;uJIF1KHSqckG5PUBqdiCqdX3hckBCOjd6MDDj[Yxtew>? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd4MkKzPEc,OTl5NkKyN|g9N2F-
A2780 MX\GeY5kfGmxbjDhd5NigQ>? NIfhPHVKdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBPWE1icHjvd5Bpd3K7bHH0bY9vKGG2IITodlE6QSCrbjDoeY1idiCDMke4NEBk\Wyucx?= M3zHR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNE[wPFQzLz5|MES2NFg1OjxxYU6=
A2780 NFTRRYpHfW6ldHnvckBie3OjeR?= NEXTXlFKdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBPWE1icHjvd5Bpd3K7bHH0bY9vKGG2IITodlE6QSCrbjDoeY1idiCDMke4NEBk\Wyucx?= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3OUKxOEc,OjN4NUmyNVQ9N2F-
A2780 M{fCWmZ2dmO2aX;uJIF{e2G7 M3TqbmlvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJG5RVSCyaH;zdIhwenmuYYTpc44h[XRidHjyNVk6KGmwIHj1cYFvKEF{N{iwJINmdGy| MlznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7M{S0OVcoRjF4OUO0OFU4RC:jPh?=
A2780 NWTYT2djTnWwY4Tpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKGOmaz3t[YRq[XSnZDDOVG0heGixc4Doc5J6dGG2aX;uJIF1KHSqckG5PUBqdiCqdX3hckBCOjd6MDDj[Yxtew>? NFT5Om89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO3NlY2Oyd-Mk[zO|I3PTN:L3G+
A2780 NF7wfWVHfW6ldHnvckBie3OjeR?= NVLxT3dlUW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhVlCPIIDoc5NxcG:{eXzheIlwdiCjdDD0bJIyQTliaX6gbJVu[W5iQUK3PFAh[2WubIO= M1vZZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
A2780 MXnGeY5kfGmxbjDhd5NigQ>? M2DuWmlvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJG5RVSCyaH;zdIhwenmuYYTpc44h[XRidHjyNVk6KGmwIHj1cYFvKEF{N{iwJINmdGy| NXjZZmFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN|k2PzVpPkOwNVM6PTd3PD;hQi=>
A2780 MUTGeY5kfGmxbjDhd5NigQ>? MVHJcohq[mm2aX;uJI9nKGOmaz3t[YRq[XSnZDDOVG0heGixc4Doc5J6dGG2aX;uJIF1KHSqckG5PUBqdiCqdX3hckBCOjd6MDDj[Yxtew>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5MUG4NEc,Ojd5N{GxPFA9N2F-
YT M4qwZ2Z2dmO2aX;uJIF{e2G7 MXuzNEBv\y:vbB?= NELKZVBKdmirYnn0bY9vKG:oIFnMNk1qdmS3Y3XkJGpCUzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFmWIHPlcIx{KGG2IEOwJI5oN22uIHL5JIludXWwb3Lsc5R1cW6pIHHuZYx6e2m| M{fRWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
YT Ml7USpVv[3Srb36gZZN{[Xl? M3PvfFMxKG6pL33s M3LNPWlvcGmkaYTpc44hd2ZiSVyyMYlv\HWlZXSgV3RCXDWDIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiC\VDDj[YxteyCjdDCzNEBv\y:vbDDifUBqdW23bn;icI91fGmwZzDhcoFtgXOrcx?= M1:1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
YT MV3GeY5kfGmxbjDhd5NigQ>? M2rIe|MxKG6pL33s MULJcohq[mm2aX;uJI9nKEmOMj3pcoR2[2WmIGPURXQ2SiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hYVRiY3XscJMh[XRiM{CgcocwdWxiYomgbY1ufW6xYnzveJRqdmdiYX7hcJl{cXN? NEmyTJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
NK MUTJcY12dm:|dYDwdoV{e2m4ZTDhd5NigQ>? M{\1cFEhfG9iNTDt[{9s\w>? M3X4T|Qhf2Wna4O= NWLTWYprUW2vdX7vd5VxeHKnc4PpeoUh[WO2aY\peJkhcW5ibnHpeoUh[3mwb33vcId2eyCvb37r[Zkh[XO|ZYPz[YQh[XNiZX\m[YN1KG:wIFPEN{1ETDF4KzDOT{Bk\WyuczDheEAyKHSxIEWgcYcwc2duIIDvJIZweiB2IIfl[Yt{ NYPSWnJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
T-cells NX\HSHhITnWwY4Tpc44h[XO|YYm= M17mdlUhfG9iNUCwJI5O MnXTNUBpeg>? M3jxbWlvcGmkaYTpc44hd2ZiSVyyMYlv\HWlZXSgV5RifDVicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEOGNDugWEBk\WyuczDheEA2KHSxIEWwNEBvVSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfA>? NGHiN409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC1N|c2Pid-MUmwOVM4PTZ:L3G+
SUM149PT M4rtSWZ2dmO2aX;uJIF{e2G7 M1jqOFMhfU1? NUj6[XlyOTZiaILz M1f2OGlv\HWldHnvckBw\iCSVGDOOkBqdiCqdX3hckBUXU1zNEnQWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCB|IIXNJIFnfGW{IEG2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m|IHnuJJBz\XOnbnPlJI9nKHCnco\hcoFl[XSn Mo\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{ixNVIoRjJ2OUe4NVEzRC:jPh?=
Hs578T NYC0OXRxTnWwY4Tpc44h[XO|YYm= NGiyW2g{KHWP MoflNVYhcHK| NUnieXp1UW6mdXP0bY9vKG:oIGDUVG43KGmwIHj1cYFvKEi|NUe4WEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCB|IIXNJIFnfGW{IEG2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m|IHnuJJBz\XOnbnPlJI9nKHCnco\hcoFl[XSn NWL3TIV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5O|gyOTJpPkK0PVc5OTF{PD;hQi=>
T-cells NIn2RY9HfW6ldHnvckBie3OjeR?= MnGzOVAhfG9iM{CwJI5O NWP1VHpXOSCqch?= NVHQXnFKUW6qaXLpeIlwdiCxZjDKRWsyN0qDS{OgbY4hcHWvYX6gR2Q1KHCxc3n0bZZmKFRiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBKVDRvc4TpcZVt[XSnZDDTWGFVPiCyaH;zdIhwenmuYYTpc44h[XRiNUCgeI8hOzByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDJUE01KHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= Mly1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUKwOlgoRjJ7OEWyNFY5RC:jPh?=
T-cells MX;GeY5kfGmxbjDhd5NigQ>? NXSyT|E3PTBidH:gN|AxKG6P M3nPOVEhcHJ? MUPJcohq[mm2aX;uJI9nKEqDS{GvTmFMOyCrbjDoeY1idiCFRESgdI9{cXSrdnWgWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMNk1{fGmvdXzheIVlKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDheEBVgXJvNkm1JJJme2mmdXWgZZQhPTBidH:gN|AxKG6PIIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCLTD2yJJN1cW23bHH0bY9vKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? M2S4XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWyNFY5Lz5{OUi1NlA3QDxxYU6=
T-cells M{K2T2Z2dmO2aX;uJIF{e2G7 NX\X[HN{RjNyMDDuUS=> MornNUBpeg>? NVG3PZJzUW6qaXLpeIlwdiCxZjDKRWsyN0qDS{KvWHlMOiCrbjDoeY1idiCFRESgdI9{cXSrdnWgWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnMOk1{fGmvdXzheIVlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEA,OzByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDJUE03KHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= Mon5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUKwOlgoRjJ7OEWyNFY5RC:jPh?=
TALL-1 MY\GeY5kfGmxbjDhd5NigQ>? NVvCbY14OSC3TR?= NUTGWnFuOyCqcoO= MnXITY5pcWKrdHnvckBw\iCMQVuzJIlvKGi3bXHuJHRCVExvMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmOLUKgbY5lfWOnZDDTWGFVPSCyaH;zdIhwenmuYYTpc44h[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFMhcHK|IH\vcIxwf2WmIHL5JGlNNTJiaX7keYN1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdITpcoc> MkXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
BA/F3 MVnGeY5kfGmxbjDhd5NigQ>? NYHlWYlDOzByIH7N M1jaOFMhcHK| NVPtNGpHUW6qaXLpeIlwdiCxZjDKRWs{KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCVVFHUOUBxcG:|cHjvdplt[XSrb36gZZQhOzByIH7NJIFnfGW{IEOgbJJ{KGK7IHntcZVvd2Kub4T0bY5oKGGwYXz5d4l{ Mom0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
OCL-AML5 MXTGeY5kfGmxbjDhd5NigQ>? MVOxJJVO MXWzJIhzew>? NHm1PXhKdmirYnn0bY9vKG:oIFrBT|IhcW5iaIXtZY4hV0OOLVHNUFUh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDHUU1EW0ZiaX7keYNm\CCVVFHUOUBxcG:|cHjvdplt[XSrb36gZZQhOSC3TTDwdoVqdmO3YnH0[YQh\m:{IEOgbJJ{KG[xbHzve4VlKGK7IFfNMWNUTiCrbnT1Z5Rqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCrbX31co9jdG:2dHnu[y=> NXn0RotKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
BA/F3 NFHMSGFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NGnlZ3I4OiCqcoO= MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegWGVNNUqDS{OgZYZ1\XJiN{KgbJJ{KGK7IHPlcIwhfGm2ZYKg[4xwKGG|c3H5 MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
BA/F3 MnzGSpVv[3Srb36gZZN{[Xl? MXKxJJVO NV;HSY1sOyCqcoO= NYey[3J[UW6qaXLpeIlwdiCxZjDKRWs{KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy|IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB|IHjyd{Bnd2yub4fl[EBjgSCydXzs[I94diC5aYToJJN1emWydHH2bYRqdiCkZXHkd{BjgSCrbX31co9jdG:2dHnu[{BidmGueYPpdy=> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
Huh7 NYX1doFkTnWwY4Tpc44h[XO|YYm= MXWxNEB2VQ>? MVyzNEBucW6| MVnJcohq[mm2aX;uJI9nKFS7a{KgbY4hcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gTWZP[WyyaHG1MYlv\HWlZXSgV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IEGwJJVOKHC{ZT3pcoN2[mG2ZXSg[o9zKDNyIH3pcpMh[mWob4LlJGlHVmGucHjhOUB{fGmvdXzheIlwdiCob4KgN|AhdWmwczDtbY5{KGK7IHntcZVvd2Kub4T0bY5o MkjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{GxOVkoRjJ4MkOxNVU6RC:jPh?=
Huh7 NXf3RXo2TnWwY4Tpc44h[XO|YYm= Ml7oNVAhfU1? M2C4c|MxKG2rboO= M3PIPWlvcGmkaYTpc44hd2ZiVInrNkBqdiCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBj[XOjbDDs[ZZmdCCVVFHUN{BxcG:|cHjvdplt[XSrb36gZZQhOTBidV2gZYZ1\XJiM{CgcYlveyCkeTDpcY12dm:kbH;0eIlv\w>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ|MUG1PUc,OjZ{M{GxOVk9N2F-
Huh7 NG\ZWGFHfW6ldHnvckBie3OjeR?= NGPXSFgyKHWP MVGzNEBucW6| MYHJcohq[mm2aX;uJI9nKFS7a{KgbY4hcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gTWZP[WyyaHG1MYlv\HWlZXSgV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGG2IEGgeW0heHKnLXnuZ5Vj[XSnZDDmc5IhOzBibXnud{Bj\W[xcnWgTWZP[WyyaHG1JJN1cW23bHH0bY9vKG[xcjCzNEBucW6|IH3pcpMh[nliaX3teY5w[myxdITpcoc> MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ|MUG1PUc,OjZ{M{GxOVk9N2F-
Assay
Methods Test Index PMID
Western blot JAK3 / STAT5 / p-STAT5 ; LMP1 / EBNA1 / BZLF1 ; JAK3 / p-JAK3 / STAT3 27732937 26082451
Growth inhibition assay Cell number 27732937
In vivo Tofacitinib citrate decrease a delayed-type hyper-sensitivity response and extended cardiac allograft survival in murine models. Furthermore, Tofacitinib citrate treatment of ex-vivo-expanded erythroid progenitors from JAK2V617F-positive PV patients results in specific, antiproliferative (IC50 = 0.2 μM) and pro-apoptotic activity. In contrast, expanded progenitors from healthy controls are less sensitive to Tofacitinib citrate in proliferation (IC50 > 1.0 μM), and apoptosis assays.[2] During 2 weeks of Tofacitinib citrate dosing at 10 and 30 mg/kg/d, a significant, time-dependent decrease in NK cell numbers relative to vehicle treatment is observed. Effector memory CD8+ cell numbers in the Tofacitinib citrate-treated group are 55% less than those observed in animals treated with vehicle.[3]

Protocol (from reference)

Kinase Assay:

[1]

  • Enzyme assays:

    The JAK1, JAK2, and JAK3 kinase assays utilize a protein expressed in baculovirus-infected SF9 cells (a fusion protein of GST and the catalytic domain of human JAK enzyme) purified by affinity chromatography on glutathione−Sepharose. The substrate for the reaction is polyglutamic acid-tyrosine [PGT (4:1)], coated onto Nunc Maxi Sorp plates at 100 μg/mL overnight at 37 °C. The plates are washed three times, and JAK enzyme is added to the wells, which contained 100 μL of kinase buffer (50 mM HEPES, pH 7.3, 125 mM NaCl, 24 mM MgCl2) + ATP + 1 mM sodium orthovanadate). For Tofacitinib citrate, it is also added for kinase assay at different doses. After incubation at room temperature for 30 min, the plates are washed three times. The level of phosphorylated tyrosine in a given well is determined by standard ELISA assay utilizing an anti-phosphotyrosine antibody.

Cell Research:

[2]

  • Cell lines: FDCP-EpoR JAK2WT and JAK2V617F cell lines
  • Concentrations: 0-4 μM
  • Incubation Time: 72 hours
  • Method:

    Determination of growth inhibition by Tofacitinib citrate is performed using identical culture conditions for both FDCP-EpoR JAK2WT and JAK2V617F cell lines. Briefly, 1 × 105 cells/mL are cultured in 96-well flat-bottom plates at 37 °C in a humidified 5% CO2 atmosphere using RPMI 1640 supplemented with 1.25% FCS, and 5% WEHI supernatant. Decreased FCS concentration is necessary to prevent binding between Tofacitinib citrate and serum proteins. Growth inhibition assays are terminated by addition of 20 μL CellTiter96 One Solution Reagent. Flat-bottom plates are incubated for an additional 3 hours for MTT assay. Absorbance is determined at 595 nm on a BioTek Synergy-HT microplate reader. Results are the average standard deviation of three independent determinations.

Animal Research:

[2]

  • Animal Models: Mauritius-origin adult cynomolgus monkeys
  • Dosages: 10, 30 mg/kg/d
  • Administration: Oral gavage

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% methylcellulose
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 504.49
Formula

C16H20N6O.C6H8O7

CAS No. 540737-29-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05082428 Active not recruiting -- Ulcerative Colitis Pfizer May 30 2022 --
NCT04768504 Recruiting Drug: Tofacitinib 10 mg Immune-Mediated Colitis Khashayar Esfahani|Sir Mortimer B. Davis - Jewish General Hospital March 22 2022 Phase 2
NCT05087589 Recruiting Drug: Tofacitinib Primary Sjögren''s Syndrome Peking University People''s Hospital November 20 2021 Phase 2
NCT04624230 Recruiting Drug: tofacitinib Ulcerative Colitis Pfizer August 12 2021 Phase 3
NCT04496960 Recruiting Drug: tofacitinib|Other: Placebo Sjogren''s Syndrome National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) May 18 2021 Phase 1|Phase 2
NCT04424303 Recruiting Drug: Tofacitinib Ulcerative Colitis Pfizer December 4 2020 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
What is the difference between the two products (S5001, S2789)?

Answer:
Tofacitinib (S2789) is the base form of Tofacitinib citrate (S5001). The biological activity of these two compound are same. S5001 is better than S2789 for Oral gavage.

Tags: buy Tofacitinib (CP-690550) Citrate | Tofacitinib (CP-690550) Citrate supplier | purchase Tofacitinib (CP-690550) Citrate | Tofacitinib (CP-690550) Citrate cost | Tofacitinib (CP-690550) Citrate manufacturer | order Tofacitinib (CP-690550) Citrate | Tofacitinib (CP-690550) Citrate distributor